Alliqua BioMedical, Inc. (NASDAQ:ALQA) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
On September 13, 2017, Alliqua BioMedical, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, the following three proposals were submitted to a vote of the Company’s stockholders:
| (1) | A proposal to ratify the filing and effectiveness of the certificate of amendment to the Company’s amended and restated certificate of incorporation (as amended) (the “Certificate of Incorporation”) filed with the Secretary of State of the State of Delaware on May 6, 2016 (the “Share Increase Amendment”), which effected an increase in the number of authorized shares of the Company’s common stock from 45,714,286 shares to 95,000,000 shares (the “Ratification Proposal”). |
| (2) | A proposal to authorize the Company’s board of directors, in its discretion, but prior to the annual meeting of the Company’s stockholders in 2018, to amend the Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1-for-3 to 1-for-13, such ratio to be determined by the board of directors and included in a public announcement (the “Reverse Stock Split Proposal”). |
| (3) | A proposal to approve an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of any of the foregoing proposals (the “Adjournment Proposal”). |
For more information about the foregoing proposals, see the Company’s definitive proxy statement filed with the Securities and Exchange Commission on August 7, 2017, the relevant portions of which are incorporated herein by reference. The number of votes cast for and against and the number of abstentions with respect to each matter voted upon are set forth below.
| (1) | Approval of the Ratification Proposal: |
| Votes For | Votes Against | Votes Abstaining |
| 35,349,194 | 2,268,603 | 404,379 |
| (2) | Approval of the Reverse Stock Split Proposal: |
| Votes For | Votes Against | Votes Abstaining |
| 34,578,140 | 3,094,649 | 349,387 |
| (3) | Approval of the Adjournment Proposal: |
| Votes For | Votes Against | Votes Abstaining |
| 30,757,149 | 6,728,593 | 536,434 |
The results reported above are final voting results. No other matters were considered or voted upon at the meeting.
About Alliqua BioMedical, Inc. (NASDAQ:ALQA)
Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers TheraBond 3D Antimicrobial Barrier Systems and SilverSeal.
